PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Oral administration significantly improved the severity of melasma in women after 12 weeks [PMID:24688621].
Demonstrated photoprotective activity, increasing minimal erythema dose and improving signs of photodamage [PMID:29908579]. It may mitigate photoaging induced by ultraviolet and visible light [PMID:34449075].
A phase IV randomized, double-blind, placebo-controlled trial found that daily treatment did not significantly reduce the mean use of topical corticosteroids in children and adolescents [PMID:2256012 la29].
While some reviews suggest it supports the prevention of skin cancers [PMID:36675602], a study in hairless mice found that oral treatment did not affect tumor onset, number, size, or growth [PMID:40439965].
Safety & adverse effects
Dosage & administration
Evidence summary
PubMed sources
- 1.PMID: 24688621 (2014) — Polypodium leucotomos as an Adjunct Treatment of Pigmentary Disorders. · The Journal of clinical and aesthetic dermatology
- 2.PMID: 25666116 (2015) — Polypodium leucotomos: a potential new photoprotective agent. · American journal of clinical dermatology
- 3.PMID: 36675602 (2023) — Uses of Polypodium leucotomos Extract in Oncodermatology. · Journal of clinical medicine
- 4.PMID: 37511888 (2023) — Clinical Applications of Polypodium leucotomos (Fernblock®): An Update. · Life (Basel, Switzerland)
- 5.PMID: 34449075 (2021) — The potential effect of Polypodium leucotomos extract on ultraviolet- and visible light-induced photoaging.